Products for Research Use Only

Oxatomide

CAT: 0804-HY-123205-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123205-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Oxatomide (KW-4354) is an orally active dual antagonist of the H1-histamine receptor and the P2X7 receptor, as well as an inhibitor of serotonin. Oxatomide possesses antihistaminic, antiallergic and anti-inflammatory activities. Oxatomide can be used in the research of allergic diseases[1][2][3][4].
CAS Number
60607-34-3
Product Name Alternative
KW-4354
UNSPSC
12352005
Hazard Statement
H302
Target
5-HT Receptor; Apoptosis; COX; Histamine Receptor; P2X Receptor; p38 MAPK; PERK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/oxatomide.html
Purity
98.11
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C1NC2=CC=CC=C2N1CCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3
Molecular Formula
C27H30N4O
Molecular Weight
426.55
Precautions
H302
References & Citations
[1] Kazuki Yoshida, et al. P2X7 receptor antagonist activity of the anti-allergic agent oxatomide. Eur J Pharmacol. 2015 Nov 15;767:41-51.|[2]Tanaka T, et al. Effect of oxatomide on otitis media with effusion--an experimental study. Acta Otolaryngol. 1995 Jul;115 (4) :532-8.|[3]Domae M, et al. The antiallergic drug oxatomide promotes human eosinophil apoptosis and suppresses IL-5-induced eosinophil survival. J Allergy Clin Immunol. 2003 Mar;111 (3) :567-72.|[4]Patella V, et al. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. Int Arch Allergy Immunol. 1996 Sep;111 (1) :23-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-2; H1 Receptor; MUC4; P2X7 Receptor